|Bid||4.4300 x 3000|
|Ask||4.4400 x 3200|
|Day's Range||4.3200 - 4.5000|
|52 Week Range||1.6800 - 6.0200|
|Beta (5Y Monthly)||1.94|
|PE Ratio (TTM)||88.60|
|Earnings Date||Aug 11, 2021 - Aug 16, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.25|
Accuray Incorporated (NASDAQ: ARAY) today announced it has entered into a new five-year $80 million term loan and $40 million revolving credit facility with Silicon Valley Bank and a syndicate of banks (the "New Credit Facility"). The closing and funding of the New Credit Facility is subject to customary conditions precedent that are anticipated to be satisfied after the date hereof. The proceeds from the New Credit Facility, plus available cash on hand, are anticipated to be used to repay all outstanding borrowings under the Company's existing term loan and revolving credit facility with MidCap Financial (the "Refinanced Credit Facilities"). The new revolving credit facility, $25 million of which is anticipated to be drawn at closing, can be used for working capital, other general corporate purposes and for other permitted uses. Relative to the Refinanced Credit Facilities, the New Credit Facility significantly reduces borrowing costs while increasing operating flexibility through less restrictive financial covenants and access to higher levels of revolver borrowings.
Accuray Incorporated (NASDAQ: ARAY) today announced that it has entered into privately negotiated agreements with the holders of its existing 3.75% senior convertible notes due 2022 (the "2022 Notes") to exchange an aggregate of $82.1 million principal amount of 2022 Notes for approximately $97.1 million aggregate principal amount of a new series of 3.75% senior convertible notes due 2026 (the "New Notes" and such transaction, the "Exchange"). Accuray will also sell approximately $2.9 million aggregate principal amount of New Notes for cash (the "Subscription" and, together with the Exchange, the "Transactions"). The Transactions are expected to close on or about May 13, 2021, subject to customary closing conditions. Accuray anticipates $100.0 million in aggregate principal amount of the New Notes and $2.9 million of the 2022 Notes will be outstanding following closing of the Transactions.
Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Jean-Philippe Pignol, M.D., Ph.D., the company's new Chief Medical & Technology Officer. As a material inducement to Dr. Pignol joining the company, and in accordance with NASDAQ Listing Rule 5635(c)(4), the Board approved granting Dr. Pignol (i) an award of 53,191 restricted stock units covering shares of the company's common stock, and (ii) a stock option to purchase 96,480 shares of the company's common stock, in each case effective as of April 30, 2021 (collectively, the "Inducement Awards"). The Inducement Awards were made outside of the company's current equity plan, but are subject to terms and conditions generally consistent with those in the company's 2016 Equity Incentive Plan.